Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma

JAMA

Volumn 311, Issue 6, 2014, Pages 597-603

  Herweijer, Eva ^a   Leval, Amy ^a,b   Ploner, Alexander ^a   Eloranta, Sandra ^a   Simard, Julia Fridman ^a   Dillner, Joakim ^a   Netterlid, Eva ^c,d,e   Sparén, Par̈ ^a   Arnheim Dahlstrom̈, Lisen ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Communicable Disease Control and Prevention for Stockholm County ^*  (Sweden)

^c Swedish Institute for Communicable Disease Control   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BIOSTATISTICS; CANCER INCIDENCE; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; DISEASE REGISTRY; DOSE RESPONSE; EDUCATIONAL STATUS; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE RATE DIFFERENCE; INCIDENCE RATE RATIO; MAJOR CLINICAL STUDY; OPEN STUDY; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SWEDEN; VACCINATION; YOUNG ADULT;

EID: 84893666624     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.95     Document Type: Article

References (31)

1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. (Pubitemid 29406813)
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(suppl 3):11-25.
3. Wiley DJ, Douglas J, Beutner K, et al. External genital warts. Clin Infect Dis. 2002;35(s2)(suppl 2):S210-S224.
4. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738. (Pubitemid 40271061)
5. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-814.
6. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971;47(1):1-13.
7. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness. J Natl Cancer Inst. 2013;105(7):469-474.
8. Kreimer AR, Rodriguez AC, Hildesheim A, et al CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-1451.
9. Natunen K, Lehtinen J, Namujju P, Sellors J, Lehtinen M. Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol. 2011;2011:675858.
10. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Hum Vaccin. 2011;7(12):1374-1386.
11. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines. BMJ. 2011;343:d5775-d5775.
12. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women. JAMA. 2013;309(17):1793-1802.
13. Krajden M, Cook D, Yu A, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011;18(3):418-423.
14. Castle PE, Zhao F-H. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis. 2011;204(3):335-337.
15. Weinberg GA, Szilagyi PG. Vaccine epidemiology. J Infect Dis. 2010;201(11):1607-1610.
16. Jensen KE, Munk C, Sparen P, et al.Women's sexual behavior. Acta Obstet Gynecol Scand. 2011;90(5):459-467.
17. Dillner J, Kjaer SK, Wheeler CM, et al; FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts. BMJ. 2010;341:c3493-c3493.
18. Paavonen J, Naud P, Salmerón J, et al HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA). Lancet. 2009;374(9686):301-314.
19. Ali H, Donovan B,Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme. BMJ. 2013;346:f2032-f2032.
20. Bauer HM,Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts. Am J Public Health. 2012;102(5):833-835.
21. Flagg EW, Schwartz R,Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010. Am J Public Health. 2013;103(8):1428-1435.
22. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States. J Infect Dis. 2013;208(3):385-393.
23. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012;30(37):5496-5499.
24. BlombergM, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus. Clin Infect Dis. 2013;57(7):929-934.
25. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years. MMWR Morb Mortal Wkly Rep. 2012;61(34):671-677.
26. Fagot J-P, Boutrelle A, Ricordeau P,Weill A, Allemand H. HPV vaccination in France. Vaccine. 2011;29(19):3610-3616.
27. Li R, Li Y, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine. 2012;30(28):4284-4291.
28. Stanley M. Prophylactic HPV vaccines. Br J Cancer. 2007;96(9):1320-1323.
29. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination. Public Health Genomics. 2009;12(5-6):319-330.
30. Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013;104(4):465-472.
31. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2):e249-e256.